News
Publications and
Announcements
Our Publications
Our Announcements
Handelsblatt, Unternehmer des Tages, Andreas Bergmann
Neue Therapie nach einem Herzinfarkt – Die Firma 4TEEN4 entwickelt ein Mittel, das Patienten vor dem Tod durch Organversagen nach einem Herzinfarkt bewahren soll – ein Milliardenmarkt.
This month, Florian A. Wenzl, MD, of the Center for Molecular Cardiology at the University of Zurich, Switzerland, earned a European Society of Cardiology (ESC) Young Investigator Award (YIA) in Clinical Science. The YIA-winning study, ‘Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes’,3 identifies circulating dipeptidyl peptidase 3 (cDPP3) as a novel biomarker of cardiogenic shock and increased mortality in patients with ACS.
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae186/7644661
4TEEN4 Pharmaceuticals was awarded a 128,000 € grant from German Bundesministerium für Bildung und Forschung to as part of "KMU-innovativ - Verbundprojekt ComplianceControl: Management von IT Compliance durch Object-Centric Process Mining (OCPM)" project, being conducted in collaboration with DHC Business Solutions GmbH & Co. KG, Saarbrücken, RHEACELL GmbH & Co. KG, Heidelberg & Universität Mannheim.
Today, 4TEEN4 Pharmaceuticals announces dosing of the first subject in Phase 1 study, a single -center, randomized, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of Procizumab. Phase I study is being conducted at Radboud University, Nijmagen NL, under the supervision of Prof. Peter Pickkers.
The commencement of Phase I clinical trial represents the culmination of extensive preclinical research and rigorous safety evaluations. As we move into this clinical phase or development, we are optimistic about the potential of our investigational treatment to address unmet medical needs in Cardiogenic Shock and make a meaningful difference in the lives of patients.
4TEEN4 Management.
4TEEN4 Pharmaceuticals was awarded a 150,000 € DATIpilot grant from German Bundesministerium für Bildung und Forschung for a SURVIVE "Schnelle und zuverlässige Diagnose des kardiogenen und septischen Schocks mittels DPP3-Bluttest in der Akut- und Notfallmedizin" project.
4TEEN4 Pharmaceuticals and Boditec Med are pleased to announce signing of an out licensing agreement for the use of 4TEEN4 owned DPP3 biomarker on Boditech’s proprietary Afias and ichroma™ platforms. Boditec will develop DPP3 for the prediction and monitoring of cardiogenic shock in patients with acute coronary syndrome and acute heart failure. In addition Boditech became a shareholder of 4TEEN4 Pharmaceuticals by acquiring 3.03% stake in the company.
https://mdtoday.co.kr
https://digitalchosun.dizzo.com
Our Achievements
A recent report on the tremendous predictive value of DPP3 in patients with cardiogenic shock within the ACCOST-HH trial was chosen as one of the 3 best Abstracts out of hundreds submitted for the upcoming 2023 congress of the German Association for Intensive and Emergency Care (DIVI). The scientific congress, one of the largest of its kind in Europe, will take place from November 29th to December 01st in Hamburg / Germany.
Within the study, median circulating DPP3 concentration at baseline was 43.2 ng/mL [21.2-74] and 52% of the patients had elevated DPP3 concentrations over the pre-defined cutoff of 40 ng/mL. The number of days without the need for cardiovascular organ support (pharmacological and/ or mechanical organ support), which had been the primary endpoint of the ACCOST-HH trial, was 7 times longer in the low versus high DPP3 group (21 vs 3 days; p=0.005). Moreover, elevated DPP3 concentrations were associated with the need for mechanical organ support -not just cardiac, but also respiratory (p=0.04; mechanical ventilation) and renal support (p<0.001; renal replacement therapy). The prolonged and increased need for organ support directly translated into a much higher (74% vs 31%) mortality rate in the high DPP3 group.
The PIs commented their findings as follows:
"Our results hold strong promise for the upcoming clinical trials on the evaluation of the specific DPP3-antibody Procizumab as new breakthrough therapy in cardiogenic shock. We are very happy to hear that Procizumab has entered clinical evaluation and might be available to our patients as soon as in 2026/27."
Supported by
The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).
